Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076619" target="_blank" >RIV/00159816:_____/22:00076619 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/65269705:_____/22:00076619 RIV/00216224:14110/22:00128072

  • Výsledek na webu

    <a href="https://www.mdpi.com/1648-9144/58/10/1477" target="_blank" >https://www.mdpi.com/1648-9144/58/10/1477</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/medicina58101477" target="_blank" >10.3390/medicina58101477</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

  • Popis výsledku v původním jazyce

    Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF &lt; 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 +/- 9%. Statistically significant differences (p &lt; 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (+/- 0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (+/- 0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (+/- 0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (+/- 0.40) nmol/L, and with maximum dose (n = 74) &gt;= 120 mg/day was 1.07 (+/- 0.76) nmol/L, p &lt; 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p &lt; 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.

  • Název v anglickém jazyce

    Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

  • Popis výsledku anglicky

    Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF &lt; 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 +/- 9%. Statistically significant differences (p &lt; 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (+/- 0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (+/- 0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (+/- 0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (+/- 0.40) nmol/L, and with maximum dose (n = 74) &gt;= 120 mg/day was 1.07 (+/- 0.76) nmol/L, p &lt; 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p &lt; 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30218 - General and internal medicine

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Medicina-Lithuania

  • ISSN

    1010-660X

  • e-ISSN

    1648-9144

  • Svazek periodika

    58

  • Číslo periodika v rámci svazku

    10

  • Stát vydavatele periodika

    LT - Litevská republika

  • Počet stran výsledku

    10

  • Strana od-do

    1477

  • Kód UT WoS článku

    000873135400001

  • EID výsledku v databázi Scopus

    2-s2.0-85140586389